aztreonam has been researched along with Infections, Staphylococcal in 10 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy of aztreonam in combination with vancomycin was compared with that of gentamicin plus piperacillin as empirical antibiotic treatment for fever in 61 neutropenic patients." | 9.07 | Aztreonam plus vancomycin versus gentamicin plus piperacillin as empirical therapy for the treatment of fever in neutropenic patients: a randomised controlled study. ( Kelsey, SM; Newland, AC; Shaw, E, 1992) |
| " administration of aztreonam (A) and cefuroxime (C), 10 adult CAPD patients (pts) with peritonitis were trained to start the following treatment procedure: a) sterile collection of dialysate effluent for cultures; b) 4 rapid in-and-out exchanges with antibiotic free dialysate; c) addition of 2 g C and 2 g A to a 2-L exchange for 6-h dwell time (the same dosage was repeated once a day in the overnight exchange); d) routine CAPD exchanges." | 5.28 | Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD). ( Conte, G; Fuiano, G; Nani, E; Sepe, V; Viscione, M, 1989) |
| "The efficacy of aztreonam in combination with vancomycin was compared with that of gentamicin plus piperacillin as empirical antibiotic treatment for fever in 61 neutropenic patients." | 5.07 | Aztreonam plus vancomycin versus gentamicin plus piperacillin as empirical therapy for the treatment of fever in neutropenic patients: a randomised controlled study. ( Kelsey, SM; Newland, AC; Shaw, E, 1992) |
| " Adverse events were reported in 46 (41." | 2.77 | A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. ( Arbeit, RD; Draper, MP; Hait, H; Noel, GJ; Tanaka, SK, 2012) |
| " Equally important is the need to provide therapy that is safe and well tolerated." | 2.75 | Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. ( Corrado, ML, 2010) |
| " administration of aztreonam (A) and cefuroxime (C), 10 adult CAPD patients (pts) with peritonitis were trained to start the following treatment procedure: a) sterile collection of dialysate effluent for cultures; b) 4 rapid in-and-out exchanges with antibiotic free dialysate; c) addition of 2 g C and 2 g A to a 2-L exchange for 6-h dwell time (the same dosage was repeated once a day in the overnight exchange); d) routine CAPD exchanges." | 1.28 | Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD). ( Conte, G; Fuiano, G; Nani, E; Sepe, V; Viscione, M, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corey, GR | 2 |
| Wilcox, MH | 2 |
| Talbot, GH | 2 |
| Thye, D | 2 |
| Friedland, D | 2 |
| Baculik, T | 2 |
| Corrado, ML | 1 |
| Noel, GJ | 1 |
| Draper, MP | 1 |
| Hait, H | 1 |
| Tanaka, SK | 1 |
| Arbeit, RD | 1 |
| Ilahi, OA | 1 |
| Swarna, U | 1 |
| Hamill, RJ | 1 |
| Young, EJ | 1 |
| Tullos, HS | 1 |
| Wertheim, H | 1 |
| Verbrugh, HA | 1 |
| van Pelt, C | 1 |
| de Man, P | 1 |
| van Belkum, A | 1 |
| Vos, MC | 1 |
| Iakovlev, VP | 1 |
| Kelsey, SM | 1 |
| Shaw, E | 1 |
| Newland, AC | 1 |
| Fuiano, G | 1 |
| Sepe, V | 1 |
| Viscione, M | 1 |
| Nani, E | 1 |
| Conte, G | 1 |
| Okura, K | 1 |
| Haruta, T | 1 |
| Yamamoto, H | 1 |
| Kuroki, S | 1 |
| Kobayashi, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection[NCT00424190] | Phase 3 | 698 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection (cSSSI)[NCT00423657] | Phase 3 | 680 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Cure: Total resolution of all signs and symptoms of the baseline infection, or improvement of the infection such that no further antimicrobial therapy was necessary.~Failure: Requirement of alternative antimicrobial therapy for primary infection of cSSSI due to inadequate response, recurrence, new infection at the same site; treatment-limiting adverse event (AE); requirement for surgery due to failure of study drug; diagnosis of osteomyelitis after Study Day 8; or death caused by cSSSI.~Indeterminate: Inability to determine an outcome" (NCT00424190)
Timeframe: 8-15 days after the end of treatment
| Intervention | participants (Number) | ||
|---|---|---|---|
| Clinical Cure | Clinical Failure | Indeterminate | |
| Ceftaroline Fosamil for Injection | 304 | 29 | 18 |
| IV Vancomycin Plus IV Aztreonam | 297 | 21 | 29 |
"Cure: Total resolution of all signs and symptoms of the baseline infection, or improvement of the infection such that no further antimicrobial therapy was necessary.~Failure: Requirement of alternative antimicrobial therapy for primary infection of complicated skin and skin structure infection (cSSSI) due to inadequate response, recurrence, new infection at the same site; treatment-limiting adverse event (AE); requirement for surgery due to failure of study drug; diagnosis of osteomyelitis after Study Day 8; or death caused by cSSSI.~Indeterminate: Inability to determine an outcome" (NCT00423657)
Timeframe: 8-15 days after last dose of study drug administration
| Intervention | participants (Number) | ||
|---|---|---|---|
| Clinical Cure | Clinical Failure | Indeterminate | |
| Ceftaroline for Injection | 291 | 25 | 26 |
| IV Vancomycin Plus IV Aztreonam | 289 | 28 | 21 |
2 reviews available for aztreonam and Infections, Staphylococcal
| Article | Year |
|---|---|
Concomitant crystal and septic arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Arthritis, Infectious; Aztreonam; Escherichia coli | 1996 |
[Aztreonam].
Topics: Aztreonam; Drug Evaluation; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; In Vitro Tech | 1992 |
5 trials available for aztreonam and Infections, Staphylococcal
3 other studies available for aztreonam and Infections, Staphylococcal
| Article | Year |
|---|---|
Improved detection of methicillin-resistant Staphylococcus aureus using phenyl mannitol broth containing aztreonam and ceftizoxime.
Topics: Aztreonam; Bacteriological Techniques; Ceftizoxime; Cephalosporins; Culture Media; Humans; Mannitol; | 2001 |
Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD).
Topics: Aztreonam; Cefuroxime; Drug Administration Schedule; Drug Therapy, Combination; Evaluation Studies a | 1989 |
[Penetration of aztreonam and ampicillin to cerebrospinal fluid in the concomitant administration to rabbits with Staphylococcus aureus meningitis].
Topics: Ampicillin; Animals; Aztreonam; Drug Combinations; Injections, Intravenous; Kinetics; Meningitis; Ra | 1985 |